Statement Of Cash Flows [Abstract]

Xspray Pharma - Filing #679275

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
- SEK
- SEK
179 667 SEK
179 667 SEK
- SEK
SEK
SEK
131 670 SEK
131 670 SEK
- SEK
SEK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories
35 229 SEK
- SEK
Adjustments for depreciation and amortisation expense
9 194 SEK
9 533 SEK
Adjustments for unrealised foreign exchange losses (gains)
41,000 SEK
SEK
Interest paid, classified as operating activities
1 169 SEK
147,000 SEK
Interest received, classified as operating activities
1 969 SEK
1 611 SEK
Cash flows from (used in) operating activities
203 275 SEK
110 179 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
2 692 SEK
24 466 SEK
Cash flows from (used in) investing activities
65 876 SEK
135 345 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
297 924 SEK
100 000 SEK
Proceeds from borrowings, classified as financing activities
45 000 SEK
Payments of lease liabilities, classified as financing activities
1 651 SEK
2 128 SEK
Cash flows from (used in) financing activities
315 594 SEK
93 809 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
46 443 SEK
151 715 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
306,000 SEK
Cash and cash equivalents
166 303 SEK
120 166 SEK
271 881 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.